Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Income: 2019-2024

Historic Operating Income for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$201.1 million.

  • Centessa Pharmaceuticals' Operating Income fell 15.91% to -$53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 32.26%. This contributed to the annual value of -$201.1 million for FY2024, which is 17.38% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Operating Income of -$201.1 million as of FY2024, which was down 17.38% from -$171.3 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Operating Income peaked at -$10.4 million during FY2020, and registered a low of -$374.1 million during FY2021.
  • Its 3-year average for Operating Income is -$194.9 million, with a median of -$201.1 million in 2024.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Operating Income tumbled by 3,483.18% in 2021 and then skyrocketed by 43.26% in 2022.
  • Centessa Pharmaceuticals' Operating Income (Yearly) stood at -$10.4 million in 2020, then crashed by 3,483.18% to -$374.1 million in 2021, then surged by 43.26% to -$212.3 million in 2022, then rose by 19.31% to -$171.3 million in 2023, then fell by 17.38% to -$201.1 million in 2024.